Literature DB >> 17110374

Insertion and topology of normal and mutant bestrophin-1 in the endoplasmic reticulum membrane.

Vladimir M Milenkovic1, Andrea Rivera, Franziska Horling, Bernhard H F Weber.   

Abstract

The vitelliform macular dystrophy type 2 (VMD2) gene mutated in Best macular dystrophy encodes a 585-amino acid putative transmembrane protein termed bestrophin-1. The vast majority of known disease-associated alterations are of the missense type, which cluster near predicted transmembrane domains (TMDs). To investigate bestrophin-1 membrane topology and to assess consequences of point mutations on membrane integration, we have analyzed the insertion of putative TMDs into the endoplasmic reticulum (ER) membrane. Out of six potential TMDs, our data suggest a topological model of bestrophin-1 with four transmembrane-spanning segments and one large cytoplasmatic loop between putative TMD2 and TMD5. Consequently, a relatively hydrophobic segment containing putative TMD3 (aa 130-149) and TMD4 (aa 179-201) is located within the cytoplasm. Furthermore, we show that three out of 18 disease-associated alterations investigated (I73N, Y85H, F281del) reveal measurable effects on membrane insertion suggesting that defective membrane integration of bestrophin-1 may represent a potential disease mechanism for a small subset of Best macular dystrophy-related mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17110374     DOI: 10.1074/jbc.M607383200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  The GABAA receptor alpha1 subunit epilepsy mutation A322D inhibits transmembrane helix formation and causes proteasomal degradation.

Authors:  Martin J Gallagher; Li Ding; Ankit Maheshwari; Robert L Macdonald
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

Review 2.  Calcium-dependent chloride conductance in epithelia: is there a contribution by Bestrophin?

Authors:  Karl Kunzelmann; Vladimir M Milenkovic; Melanie Spitzner; René Barro Soria; Rainer Schreiber
Journal:  Pflugers Arch       Date:  2007-03-15       Impact factor: 3.657

3.  A variant of the Ca2+-activated Cl channel Best3 is expressed in mouse exocrine glands.

Authors:  Alaka Srivastava; Victor G Romanenko; Mireya Gonzalez-Begne; Marcelo A Catalán; James E Melvin
Journal:  J Membr Biol       Date:  2008-03       Impact factor: 1.843

Review 4.  Protein misfolding and retinal degeneration.

Authors:  Radouil Tzekov; Linda Stein; Shalesh Kaushal
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-11-01       Impact factor: 10.005

5.  Altered intracellular localization and valosin-containing protein (p97 VCP) interaction underlie ATP7A-related distal motor neuropathy.

Authors:  Ling Yi; Anthony Donsante; Marina L Kennerson; Julian F B Mercer; James Y Garbern; Stephen G Kaler
Journal:  Hum Mol Genet       Date:  2011-12-30       Impact factor: 6.150

6.  Modeling the structural consequences of BEST1 missense mutations.

Authors:  Karina E Guziewicz; Gustavo D Aguirre; Barbara Zangerl
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Bestrophin-2 is involved in the generation of intraocular pressure.

Authors:  Benjamin Bakall; Precious McLaughlin; J Brett Stanton; Youwen Zhang; H Criss Hartzell; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

8.  Stoichiometry and specific assembly of Best ion channels.

Authors:  Shashank Bharill; Zhu Fu; Raz Palty; Ehud Y Isacoff
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-18       Impact factor: 11.205

Review 9.  Functional roles of bestrophins in ocular epithelia.

Authors:  Alan D Marmorstein; Harold E Cross; Neal S Peachey
Journal:  Prog Retin Eye Res       Date:  2009-05-04       Impact factor: 21.198

10.  Dysregulation of human bestrophin-1 by ceramide-induced dephosphorylation.

Authors:  Qinghuan Xiao; Kuai Yu; Yuan-Yuan Cui; H Criss Hartzell
Journal:  J Physiol       Date:  2009-07-27       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.